Premium
Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology
Author(s) -
Carroll Kevin J.
Publication year - 2007
Publication title -
pharmaceutical statistics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.421
H-Index - 38
eISSN - 1539-1612
pISSN - 1539-1604
DOI - 10.1002/pst.269
Subject(s) - drug development , drug , biomarker , medicine , clinical trial , risk analysis (engineering) , intensive care medicine , medical physics , oncology , pharmacology , biology , biochemistry
Abstract Hopes and expectations for the use and utility of new, emerging biomarkers in drug development have probably never been higher, especially in oncology. Biomarkers are exalted as vital patient selection tools in an effort to target those most likely to benefit from a new drug, and so to reduce development costs, lessen risk and expedite developments times. It is further hoped that biomarkers can be used as surrogate endpoints for clinical outcomes, to demonstrate effectiveness and, ultimately, to support drug approval. However, I perceive that all is not straightforward, and, particularly in terms of the promise of accelerated drug development, biomarker strategies may not in all cases deliver the advances and advantages hoped for. Copyright © 2007 John Wiley & Sons, Ltd.